Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCL NASDAQ:IMCR NASDAQ:PRTC NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$5.66-0.9%$4.93$1.89▼$6.51$1.71B0.696.09 million shs4.69 million shsIMCRImmunocore$33.10+4.7%$33.82$23.15▼$39.33$1.59B0.79364,021 shs248,254 shsPRTCPureTech Health$17.50+5.0%$17.50$13.30▼$24.99$402.60M1.131,933 shs3,863 shsTLRYTilray Brands$1.49+0.7%$1.38$0.35▼$2.32$1.66B1.98115.54 million shs48.25 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics-0.88%+1.25%+18.66%+10.76%+103.60%IMCRImmunocore+4.75%-1.37%-3.41%-5.89%+3.37%PRTCPureTech Health-1.20%-2.79%+1.09%-8.79%-14.27%TLRYTilray Brands+0.68%-4.49%+18.25%+116.41%-11.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$5.66-0.9%$4.93$1.89▼$6.51$1.71B0.696.09 million shs4.69 million shsIMCRImmunocore$33.10+4.7%$33.82$23.15▼$39.33$1.59B0.79364,021 shs248,254 shsPRTCPureTech Health$17.50+5.0%$17.50$13.30▼$24.99$402.60M1.131,933 shs3,863 shsTLRYTilray Brands$1.49+0.7%$1.38$0.35▼$2.32$1.66B1.98115.54 million shs48.25 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics-0.88%+1.25%+18.66%+10.76%+103.60%IMCRImmunocore+4.75%-1.37%-3.41%-5.89%+3.37%PRTCPureTech Health-1.20%-2.79%+1.09%-8.79%-14.27%TLRYTilray Brands+0.68%-4.49%+18.25%+116.41%-11.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 2.71Moderate Buy$8.0041.34% UpsideIMCRImmunocore 2.45Hold$61.0084.29% UpsidePRTCPureTech Health 1.00SellN/AN/ATLRYTilray Brands 2.00Hold$2.0034.23% UpsideCurrent Analyst Ratings BreakdownLatest PRTC, ABCL, TLRY, and IMCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025ABCLAbCellera BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025TLRYTilray BrandsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/22/2025IMCRImmunocoreHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.0010/9/2025TLRYTilray BrandsAtb Cap MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell10/8/2025ABCLAbCellera BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IMCRImmunocoreWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025PRTCPureTech HealthWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025TLRYTilray BrandsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ABCLAbCellera BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IMCRImmunocoreWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025PRTCPureTech HealthWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$28.83M58.67N/AN/A$3.58 per share1.58IMCRImmunocore$310.20M5.38N/AN/A$7.20 per share4.60PRTCPureTech Health$4.83M87.56$2.50 per share6.99$17.04 per share1.03TLRYTilray Brands$210.48M7.95$0.15 per share10.24$1.35 per share1.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$162.86M-$0.55N/AN/AN/A-511.88%-16.17%-12.24%11/6/2025 (Confirmed)IMCRImmunocore-$51.09M-$0.40N/AN/AN/A-5.70%-5.40%-1.93%11/5/2025 (Estimated)PRTCPureTech Health$27.78MN/A0.00N/AN/AN/AN/AN/AN/ATLRYTilray Brands-$2.19B-$2.27N/AN/AN/A-258.54%-6.79%-5.30%1/9/2026 (Estimated)Latest PRTC, ABCL, TLRY, and IMCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ABCLAbCellera Biologics-$0.17N/AN/AN/A$6.33 millionN/A11/5/2025Q3 2025IMCRImmunocore-$0.30N/AN/AN/A$137.29 millionN/A10/9/2025Q1 2026TLRYTilray Brands-$0.03-$0.0002+$0.0298N/A$205.75 million$209.50 million8/7/2025Q2 2025ABCLAbCellera Biologics-$0.17-$0.12+$0.05-$0.12$7.55 million$17.08 million8/7/2025Q2 2025IMCRImmunocore-$0.21-$0.20+$0.01-$0.20$122.96 million$130.65 million7/28/2025Q4 2025TLRYTilray Brands-$0.03$0.02+$0.05-$1.30$250.41 million$224.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A11.0711.07IMCRImmunocore1.015.895.86PRTCPureTech HealthN/A8.49N/ATLRYTilray Brands0.152.621.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%IMCRImmunocore84.50%PRTCPureTech Health0.04%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.90%IMCRImmunocore10.40%PRTCPureTech Health5.30%TLRYTilray Brands0.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500298.83 million212.47 millionOptionableIMCRImmunocore32050.39 million45.15 millionOptionablePRTCPureTech Health10024.17 million22.89 millionNot OptionableTLRYTilray Brands2,8421.12 billion1.11 billionOptionablePRTC, ABCL, TLRY, and IMCR HeadlinesRecent News About These CompaniesTilray Brands' (TLRY) "Sell (D-)" Rating Reiterated at Weiss RatingsOctober 24 at 12:42 AM | marketbeat.comTop Cannabis Stocks To Add to Your Watchlist - October 24thOctober 24 at 1:57 PM | marketbeat.comTilray Brands, Inc. (TLRY): A Bull Case TheoryOctober 24 at 4:31 AM | finance.yahoo.comTilray Brands (NASDAQ:TLRY) Trading 2.1% Higher - Should You Buy?October 23 at 5:36 PM | marketbeat.comCannabis Stocks To Watch Today - October 23rdOctober 23 at 2:09 PM | marketbeat.comCanadian Cannabis Leaders Poised for Growth as U.S. Legalization Momentum BuildsOctober 23 at 10:00 AM | marijuanastocks.comMRedhook Brewing Launches Redhook 81, Celebrating Pacific Northwest Roots and the Spirit of Hard WorkOctober 23 at 7:00 AM | globenewswire.comTilray Brands (NASDAQ:TLRY) Trading Down 2% - Should You Sell?October 22 at 5:39 PM | marketbeat.comCannabis Stocks To Follow Today - October 22ndOctober 22 at 12:46 PM | marketbeat.comTilray Brands Stock Is on Track for Its Best Year Since 2018. Has It Become a Good Buy?October 22 at 5:30 AM | fool.comTilray Brands (NASDAQ:TLRY) Shares Down 5.7% - What's Next?October 21, 2025 | marketbeat.comPromising Cannabis Stocks To Watch Today - October 21stOctober 21, 2025 | marketbeat.comTop Cannabis Stocks To Follow Now - October 20thOctober 20, 2025 | marketbeat.comIf You'd Invested $500 in Tilray Brands 5 Years Ago, Here's How Much You'd Have TodayOctober 20, 2025 | fool.comTop Cannabis Stocks To Keep An Eye On - October 19thOctober 19, 2025 | marketbeat.comCannabis Stocks To Keep An Eye On - October 18thOctober 18, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Trading 1.3% Higher - Should You Buy?October 17, 2025 | marketbeat.comCannabis Stocks To Watch Today - October 17thOctober 17, 2025 | marketbeat.comTilray Brands Marks Seven Years of Cannabis Legalization in Canada with the #1 Market-Leading Position by Revenue and Pioneering Brands with Growing Market Share in the World's Largest Federally Legal Cannabis MarketOctober 17, 2025 | globenewswire.comTilray Brands, Inc. (NASDAQ:TLRY) Receives $2.00 Average PT from BrokeragesOctober 17, 2025 | americanbankingnews.comStock Traders Buy High Volume of Call Options on Tilray Brands (NASDAQ:TLRY)October 17, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Is Tilray's Stock Price Surge a Pipe Dream of Political Hype?By Jeffrey Neal Johnson | October 1, 2025PRTC, ABCL, TLRY, and IMCR Company DescriptionsAbCellera Biologics NASDAQ:ABCL$5.66 -0.05 (-0.88%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$5.70 +0.04 (+0.71%) As of 10/24/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Immunocore NASDAQ:IMCR$33.10 +1.50 (+4.75%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$33.14 +0.03 (+0.11%) As of 10/24/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.PureTech Health NASDAQ:PRTC$17.62 +0.96 (+5.79%) As of 10/24/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Tilray Brands NASDAQ:TLRY$1.49 +0.01 (+0.68%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.49 0.00 (0.00%) As of 10/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
